Kexing Biopharm Co., Ltd.SSE: 688136

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of GB10 for Injection

· Issued by Kexing Biopharm Co., Ltd. via Shanghai Stock Exchange

Filed with SSE ·

On 6ix: 6ix.com/news/announcement-on-voluntary-disclosure-of-completion-of-inclusion-of-the-first-subject-in-phase-1-clinical-trial-of-gb10-for-injection

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of GB10 for Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Kexing Biopharm Co., Ltd. on 6ix

Earlier from Kexing Biopharm

Later from Kexing Biopharm

All Kexing Biopharm news releases